Bullfrog AI

Historical price data

Bullfrog AI aims to transform precision medicine by applying its award-winning, graph-based AI platform to identify the right drug for the right patient at the right dose. The company operates a dual-strategy business model, advancing its own in-licensed pipeline in glioblastoma and metabolic diseases while commercializing its bfPREP™ and bfLEAP™ platforms as SaaS solutions for data harmonization and analysis. Its technology, originally developed at Johns Hopkins University Applied Physics Laboratory, is designed to uncover hidden patterns in complex, multimodal biomedical data to optimize clinical trials, discover novel targets, and identify patient subgroups.

bfLEAP™ is an explainable, graph-based AI/ML platform for analyzing complex biomedical data, complemented by bfPREP™ for data harmonization. The technology was developed at Johns Hopkins University Applied Physics Laboratory.

Bullfrog competes with AI-driven drug discovery companies like Recursion and Exscientia, differentiating through its focus on explainable AI and a dedicated data harmonization platform. In therapeutics, it faces numerous biotech and pharma companies in the competitive glioblastoma and metabolic disease landscapes.